Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VT vs XBI: how they differ
VT and XBI hold 1% of their weight in the same names, and XBI returned more over the year.
Vanguard Total World Stock Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VT and XBI hold 1% of their money in the same securities at the same weight.
| Holding | VT | XBI |
|---|---|---|
| AbbVie Inc | 0.34% | 1.04% |
| Amgen Inc | 0.17% | 1.00% |
| Gilead Sciences Inc | 0.15% | 0.97% |
| Vertex Pharmaceuticals Inc | 0.10% | 1.06% |
| Regeneron Pharmaceuticals Inc | 0.07% | 0.96% |
| Alnylam Pharmaceuticals Inc | 0.04% | 0.96% |
| Biogen Inc | 0.03% | 1.03% |
| Insmed Inc | 0.03% | 1.08% |
| Natera Inc | 0.03% | 1.17% |
| REVOLUTION Medicines Inc | 0.02% | 1.21% |
| United Therapeutics Corp | 0.02% | 0.93% |
| Incyte Corp | 0.01% | 1.00% |
| Only in VT | Only in XBI |
|---|---|
| NVIDIA Corp 4.22% | Apogee Therapeutics Inc 1.49% |
| Apple Inc 3.53% | Oruka Therapeutics Inc 1.38% |
| Microsoft Corp 2.73% | Erasca Inc 1.27% |
| Amazon.com Inc 2.29% | CG oncology Inc 1.20% |
| Alphabet Inc 2.04% | SELLAS Life Sciences Group Inc 1.19% |
| Broadcom Inc 1.74% | Dianthus Therapeutics Inc 1.19% |
| Alphabet Inc 1.61% | Mirum Pharmaceuticals Inc 1.16% |
| Taiwan Semiconductor Manufacturing Co Lt 1.52% | Roivant Sciences Ltd 1.16% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| VT Vanguard Total World Stock Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Total World Stock | SPDR S&P Biotech |
| Total return, 1 year | +18.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +1.4 pts | +46.5 pts |
| Expense ratio | 0.06% | 0.35% |
| Already in the S&P 500 | 55.2% | 8.5% |
| Holdings | 10042 | 150 |
VT in plain words
VT is an index equity fund tracking the Total World Stock. Over the year to Sep 11, 2026 it returned +18.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.06% a year. By its holdings filed for Apr 30, 2026, 55% of the fund by weight is stocks the S&P 500 also holds, across 10042 positions, with the top ten at 21.9%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VT or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VT returned +18.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VT or XBI?
- VT charges 0.06% a year and XBI charges 0.35%, so VT is cheaper. Fees come from each fund's prospectus.
- How much do VT and XBI overlap with the S&P 500?
- By their latest filed holdings, 55% of VT and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VT against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VT-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources